Autopsy report · NCT01999803
A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS
Cause of deathFutility, also drug or device supply
“Issues with development and supply of infusion system for delivery of IMP. Lack of favorable benefit risk ratio in sNN0029-003 study (review of interim data).”
Life of this trial
- Registered 10 months before it started.
- Ran for about 1 year 1 month before it stopped.
- 15 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Newron Sweden AB
- Sponsor type
- Industry
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- sNN0029; Placebo
- Participants
- 15
- Sites
- 2
- Countries
- Belgium, Netherlands
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.